Table 1.

What to do with rheumatic/gastroenterological immunosuppressive treatment in COVID-19- and COVID-19+ patients and infection-related risk.

Drugs	COVID-19 negative	COVID-19 positive	Infectious risk
Methotrexate	Continue	Discontinue	H
Leflunomide	Continue	Discontinue	H
Hydroxychloroquine	Continue	Continue	L
Rituximab	Discontinue	Discontinue	VH
Tocilizumab	Continue	Discontinue	H
Sarilumab	Continue	Discontinue	H
Anti-TNF-α agents	Continue	Discontinue	H
Abatacept	Continue	Discontinue	H
JAK inhibitors	Continue	Discontinue	H
Anakinra	Continue	Discontinue	H
Cyclophosphamide	Discontinue	Discontinue	VH
Steroids*	Continue	Maintain low dosage	H
Ustekinumab	Continue	Discontinue	H
Baricitinb/Tofacitinib	Continue	Discontinue	H
NSAIDs	Continue	On demand	NA
Mesalazine	Continue	Continue	None
Vedolizumab	Continue	Discontinue	H
Azathioprine 6-mercaptopurine	Continued	Discontinued	H
Budesonide, Beclomethasone dipropionate	Continued	Continued	None
Cyclosporine A	Continued	Discontinued	H

*In the case of IBD relapse, consider systemic administration.

H high L low VH very high NA not assessed.